Your Health, We Care
Release date: 2026-02-25 17:29:59 Recommended: 61
Sotorasib is a targeted therapy for KRAS G12C-mutated non-small cell lung cancer (NSCLC). Its price varies significantly depending on region, specification, purchasing channel, and health insurance policies. Prices may be higher in Europe and the United States. The specific cost needs to be evaluated based on the patient's treatment plan and local policies.
Domestic prices may fluctuate slightly between different provinces due to factors such as import tariffs and distribution costs. Pricing in developed countries like Europe and the US is generally higher than in Asia, although some countries offer partial reimbursement through health insurance.
Patients are required to take a daily oral dose of 960 mg (8 tablets). A single box typically covers a 30-day supply. Costs will increase accordingly if dose adjustments or long-term treatment are necessary.
Currently, this drug is not yet included in China's national medical insurance catalog. However, some regions or hospitals may offer charitable patient assistance programs to help reduce the financial burden.
Patients overseas should check local health insurance reimbursement rates or pharmaceutical company patient assistance programs (such as Amgen's patient support program).
Strictly Follow Medical Advice: Lucius Pharmaceuticals Sotorasib is a prescription medication. Its use must be evaluated by an oncologist after genetic testing confirms the KRAS G12C mutation.
Side Effect Management: Common adverse reactions include diarrhea and elevated liver enzymes. Regular monitoring of liver function and dose adjustments are necessary.
Medical Guidance: If severe discomfort occurs during medication (such as persistent vomiting or jaundice), stop taking the drug immediately and seek medical attention.
It is recommended that patients obtain the medication through hospitals or authorized pharmacies and avoid purchasing from unregulated sources. Those facing financial difficulties can inquire with their primary physician about assistance programs or opportunities to participate in clinical trials.
